Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 141260, 4 pages
http://dx.doi.org/10.1155/2014/141260
Case Report

A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions

1Metropolitan Research Center for Blood Disorders (MRC Japan), 1-45-46 Midorigaoka, Chofu, Tokyo 182-0001, Japan
2Department of General Medicine, Shin-Yurigaoka General Hospital, Furusawa Tsuko 255, Asaoku, Kawasaki, Kanagawa 215-0026, Japan
3Department of Hematology, Shin-Yurigaoka General Hospital, Furusawa Tsuko 255, Asaoku, Kawasaki, Kanagawa 215-0026, Japan

Received 17 July 2014; Accepted 23 September 2014; Published 2 October 2014

Academic Editor: Ramon Tiu

Copyright © 2014 Yumi Yamamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Dawson, S. Avery, Z. K. McQuilten et al., “Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?” Haematologica, vol. 92, no. 7, pp. 996–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Brown, G. Keck, and P. Ford, “Acute myeloid leukemia in Jehovah Witnesses,” Leukemia and Lymphoma, vol. 49, no. 4, pp. 817–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. K. Christman, “5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy,” Oncogene, vol. 21, no. 35, pp. 5483–5495, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. E. Vigil, T. Martin-Santos, and G. Garcia-Manero, “Safety and efficacy of azacitidine in myelodysplastic syndromes,” Drug Design, Development and Therapy, vol. 4, pp. 221–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. H. van Der Helm, E. R. M. Scheepers, N. J. Veeger et al., “Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients,” Journal of Hematology and Oncology, vol. 6, no. 1, article 29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Sudan, J. M. Rossetti, R. K. Shadduck et al., “Treatment of acute myelogenous leukemia with outpatient azacitidine,” Cancer, vol. 107, no. 8, pp. 1839–1843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. R. Silverman, D. R. McKenzie, B. L. Peterson et al., “Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3895–3903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Fenaux, G. J. Mufti, E. Hellström-Lindberg et al., “Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia,” Journal of Clinical Oncology, vol. 28, no. 4, pp. 562–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. K. Al-Ali, N. Jaekel, C. Junghanss et al., “Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study,” Leukemia and Lymphoma, vol. 53, no. 1, pp. 110–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Quintás-Cardama, F. Ravandi, T. Liu-Dumlao et al., “Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia,” Blood, vol. 120, no. 24, pp. 4840–4845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Maurillo, A. Venditti, A. Spagnoli et al., “Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program,” Cancer, vol. 118, no. 4, pp. 1014–1022, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Pleyer, R. Stauder, S. Burgstaller et al., “Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group,” Journal of Hematology and Oncology, vol. 6, no. 1, article 32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. L. H. van der Helm, N. J. G. M. Veeger, M. V. M. Kooy et al., “Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts,” Leukemia Research, vol. 37, no. 8, pp. 877–882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Tawfik, S. Sliesoraitis, S. Lyerly et al., “Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML),” Annals of Hematology, vol. 93, no. 1, pp. 47–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. L. Goldberg, C. S. P. Chan, F. W. Dawkins, T. W. Mehlman, and G. Schechter, “Should Jehovah's witnesses be denied intensive chemotherapy for acute leukemia?” The New England Journal of Medicine, vol. 322, no. 11, pp. 777–778, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. J. B. Hargis, D. J. Waddell, L. Diehl, and J. Redmond, “Induction chemotherapy in Jehovah's Witnesses with leukaemia,” The Lancet, vol. 336, no. 8714, pp. 563–564, 1990. View at Google Scholar · View at Scopus
  17. G. Broccia, “Long-term continuous complete remission of acute myeloid leukemia in a Jehovah's witness treated without blood support,” Haematologica, vol. 79, no. 2, pp. 180–181, 1994. View at Google Scholar · View at Scopus
  18. Y. P. Agrawal, M. Freedman, and Z. M. Szczepiorkowski, “Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report,” Transfusion, vol. 45, no. 11, pp. 1735–1738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Dalal, M. Boddapati, M. N. Lowery, D. M. Veillon, J. Glass, and R. Munker, “Treatment of acute myeloid leukemia in a Jehovah's Witness,” Annals of Hematology, vol. 85, no. 6, pp. 407–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Bareford, B. Odeh, S. Narayanan, and S. Wiltshire, “Remission induction in a Jehovah’s Witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin,” Transfusion Medicine, vol. 15, no. 5, pp. 445–448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Kerridge, M. Lowe, M. Seldon, A. Enno, and S. Deveridge, “Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia,” Archives of Internal Medicine, vol. 157, no. 15, pp. 1753–1757, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Wandt, K. Schaefer-Eckart, and M. Wilhelm, “Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support,” Haematologica, vol. 90, no. 9, pp. 1292–1294, 2005. View at Google Scholar · View at Scopus
  23. P. Mazza, G. Palazzo, B. Amurri, M. Cervellera, C. Rizzo, and A. Maggi, “Acute leukemia in Jehovah's Witnesses: a challenge for hematologists,” Haematologica, vol. 85, no. 11, pp. 1221–1222, 2000. View at Google Scholar · View at Scopus
  24. J. O. Cullis, A. S. Duncombe, J. M. Dudley, H. S. Lumley, J. F. Apperley, and A. G. Smith, “Acute leukaemia in Jehovah's Witnesses,” British Journal of Haematology, vol. 100, no. 4, pp. 664–668, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Dainer, C. L. Knupp, and G. P. Sartiano, “Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah’s witnesses,” The American Journal of Hematology, vol. 40, no. 2, pp. 156–157, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nousiainen, E. Jantunen, and R. Lahtinen, “Jehovah's witnesses and acute leukemia,” The American Journal of Hematology, vol. 43, no. 2, pp. 158–159, 1993. View at Google Scholar · View at Scopus
  27. D. Laszlo, A. Agazzi, A. Goldhirsch et al., “Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat,” European Journal of Haematology, vol. 72, no. 4, pp. 264–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Fujisawa, K. Naito, T. Matsuoka, and M. Kobayashi, “Complete remission induced by gemtuzumab ozogamicin in a Jehovah’s Witness patient with acute myelogenous leukemia,” International Journal of Hematology, vol. 85, no. 5, pp. 418–420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. M. Stein and M. S. Tallman, “Remission induction in acute myeloid leukemia,” International Journal of Hematology, vol. 96, no. 2, pp. 164–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Ogata, E. An, K. Kamikubo et al., “Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study,” Stem Cells, vol. 16, no. 4, pp. 280–287, 1998. View at Publisher · View at Google Scholar · View at Scopus